Back to Journals » Cancer Management and Research » Volume 12

Combination of Serum miRNAs with Serum Exosomal miRNAs in Early Diagnosis for Non-Small-Cell Lung Cancer

Authors Wu Q, Yu L, Lin X, Zheng Q, Zhang S, Chen D, Pan X, Huang Y

Received 25 September 2019

Accepted for publication 21 November 2019

Published 21 January 2020 Volume 2020:12 Pages 485—495

DOI https://doi.org/10.2147/CMAR.S232383

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Qingwei Wu, 1, 2 Lili Yu, 1, 2 Xiaoqing Lin, 1, 2 Qingzhu Zheng, 1, 2 Songgao Zhang, 1, 2 Dunyan Chen, 1, 2 Xiaojie Pan, 1, 3 Yi Huang 1, 2, 4 

1Provincial Clinical College, Fujian Medical University, Fuzhou 350001, People’s Republic of China; 2Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of China; 3Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of China; 4Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of China

Correspondence: Yi Huang
Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of China
Email hyi8070@126.com

Purpose: Circulating microRNAs (miRNAs) have shown the potential for non-invasive diagnosis of various types of malignancies at an early stage. The aim of the study was to explore the feasibility of a combination of 8 serum miRNAs related to non-small-cell lung cancer (NSCLC) with the corresponding serum exosomal miRNAs in early diagnosis for the patients with NSCLC.
Methods: We measured 8 serum miRNAs and the corresponding serum exosomal miRNAs including miR-21-5p, miR-126-3p, miR-141-3p, miR-146a-5p, miR-155-5p, miR-222-3p, miR-223-3p, and miR-486-5p in 48 patients with early NSCLC at stages I/II, 32 patients with lung benign lesion (LBL), and 48 healthy control (HC) by quantitative real-time polymerase chain reaction (qRT-PCR).
Results: The expression levels of 4 serum miRNAs including miR-21-5p, miR-141-3p, miR-222-3p, and miR-486-5p, and 2 serum exosomal miRNAs including miR-146a-5p and miR-486-5p in the early NSCLC group were significantly different from that in the LBL group and the HC group (P < 0.01). The areas under the receiver operating characteristic curves (AUC) of the 4 serum miRNAs and 2 serum exosomal miRNAs in the early NSCLC group were ≥ 0.697, of which serum exosomal miR-146a-5p and miR-486-5p were 0.813 and 0.886, respectively, and higher than that of the 4 serum miRNAs. Additionally, a combination of 4 serum miRNAs with 2 serum exosomal miRNAs improved the AUC to 0.960 for the patients with NSCLC at early stages, with a sensitivity of 85.42% and a specificity of 92.50%.
Conclusion: This study suggests that serum exosomal miRNAs other than serum miRNAs might be preferable biomarkers for the patients with NSCLC at early stages, and a combination of serum miRNAs with serum exosomal miRNAs contributes to the further improvement of early diagnosis for NSCLC.

Keywords: serum, exosome, microRNA, non-small-cell lung cancer, early diagnosis


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]